52U Stock Overview
Engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.66 |
| 52 Week High | €13.35 |
| 52 Week Low | €3.22 |
| Beta | 0.45 |
| 11 Month Change | -4.07% |
| 3 Month Change | -14.50% |
| 1 Year Change | -54.17% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52U | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 34.8% | -1.2% | -0.02% |
| 1Y | -54.2% | -20.1% | 8.2% |
Return vs Industry: 52U underperformed the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: 52U underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 52U volatility | |
|---|---|
| 52U Average Weekly Movement | 15.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 52U's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 52U's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 41 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address unmet medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen sodium dihydrate used for post-operative pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases.
Hyloris Pharmaceuticals SA Fundamentals Summary
| 52U fundamental statistics | |
|---|---|
| Market cap | €160.72m |
| Earnings (TTM) | -€13.24m |
| Revenue (TTM) | €6.94m |
23.2x
P/S Ratio-12.1x
P/E RatioIs 52U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52U income statement (TTM) | |
|---|---|
| Revenue | €6.94m |
| Cost of Revenue | €155.00k |
| Gross Profit | €6.79m |
| Other Expenses | €20.03m |
| Earnings | -€13.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 20, 2025
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 97.77% |
| Net Profit Margin | -190.79% |
| Debt/Equity Ratio | 0.3% |
How did 52U perform over the long term?
See historical performance and comparison